NO2009018I1 - Lasofoksifen - Google Patents
LasofoksifenInfo
- Publication number
- NO2009018I1 NO2009018I1 NO2009018C NO2009018C NO2009018I1 NO 2009018 I1 NO2009018 I1 NO 2009018I1 NO 2009018 C NO2009018 C NO 2009018C NO 2009018 C NO2009018 C NO 2009018C NO 2009018 I1 NO2009018 I1 NO 2009018I1
- Authority
- NO
- Norway
- Prior art keywords
- lasofoksifen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/369,954 US5552412A (en) | 1995-01-09 | 1995-01-09 | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
Publications (2)
Publication Number | Publication Date |
---|---|
NO2009018I1 true NO2009018I1 (no) | 2009-09-07 |
NO2009018I2 NO2009018I2 (no) | 2010-06-28 |
Family
ID=23457628
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO960081A NO305435B1 (no) | 1995-01-09 | 1996-01-08 | Ïstrogen-agonist/antagonister, farmas°ytisk preparat inneholdende disse og mellomprodukt derav |
NO2009018C NO2009018I2 (no) | 1995-01-09 | 2009-08-21 | Lasofoksifen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO960081A NO305435B1 (no) | 1995-01-09 | 1996-01-08 | Ïstrogen-agonist/antagonister, farmas°ytisk preparat inneholdende disse og mellomprodukt derav |
Country Status (46)
Families Citing this family (177)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974796B1 (en) | 1999-08-17 | 2005-12-13 | Girsh Leonard S | Therapeutic compositions for treatment of a damaged tissue |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
IL120265A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists |
CA2206752A1 (en) * | 1996-07-02 | 1998-01-02 | George Joseph Cullinan | Benzothiophene compounds, intermediates, processes, and methods of use |
ID19392A (id) * | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
CA2215856A1 (en) * | 1996-09-26 | 1998-03-26 | Eli Lilly And Company | Dihydrobenzofluorene compounds, intermediates, compositions, and methods |
CA2215647A1 (en) * | 1996-10-24 | 1998-04-24 | Eli Lilly And Company | Naphthyl compounds, compositions, and methods |
US6034102A (en) * | 1996-11-15 | 2000-03-07 | Pfizer Inc | Atherosclerosis treatment |
WO1998048806A1 (en) * | 1997-04-25 | 1998-11-05 | Eli Lilly And Company | Indene compounds having activity as serms |
KR20010020378A (ko) * | 1997-04-30 | 2001-03-15 | 피터 지. 스트링거 | 벤조티오펜의 제조 방법 |
CA2236254A1 (en) * | 1997-04-30 | 1998-10-30 | David Warren Hoard | Process for preparing benzo¬b|thiophenes |
WO1998048792A1 (en) * | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES |
CA2287922A1 (en) * | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | Intermediates and processes for preparing benzo[b]thiophenes |
CA2231013A1 (en) * | 1997-04-30 | 1998-10-30 | Eli Lilly And Company | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals |
AU7261598A (en) * | 1997-04-30 | 1998-11-24 | Eli Lilly And Company | Intermediates and a process for preparing benzo{b}thiophenes |
US6509356B1 (en) | 1997-08-07 | 2003-01-21 | Eli Lilly And Company | 1-(4-(Substituted alkoxy)benzyl)naphthalene compounds having estrogen inhibitory activity |
US6107346A (en) * | 1997-08-11 | 2000-08-22 | Eli Lilly And Company | Methods for treating hyperlipidemia |
US5908859A (en) * | 1997-08-11 | 1999-06-01 | Eli Lilly And Company | Benzothiophenes for inhibiting hyperlipidemia |
US6080773A (en) | 1997-10-14 | 2000-06-27 | Akzo Nobel, N.V. | Benzylamine derivatives which are useful in treating psychiatric disorders |
US20020037885A1 (en) * | 1999-07-22 | 2002-03-28 | Dijcks Fredericus Antonius | Therapeutic compounds |
US6384057B1 (en) | 1997-12-11 | 2002-05-07 | American Home Products Corporation | 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis |
WO1999032447A2 (en) * | 1997-12-11 | 1999-07-01 | American Home Products Corporation | 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof |
FR2778404B1 (fr) * | 1998-05-06 | 2000-06-30 | Hoechst Marion Roussel Inc | Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant |
PA8471201A1 (es) * | 1998-06-16 | 2000-09-29 | Pfizer Prod Inc | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
EP0966968B1 (en) | 1998-06-16 | 2004-05-06 | Pfizer Products Inc. | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2 |
DE19833786A1 (de) * | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
US6503917B1 (en) | 1998-12-10 | 2003-01-07 | Wyeth, Five Giralda Farms | 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof |
US6331562B1 (en) | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6291456B1 (en) | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
JP2003521468A (ja) | 1999-03-17 | 2003-07-15 | シグナル ファーマシューティカルズ, インコーポレイテッド | エストロゲンレセプタを変調させるための化合物及び方法 |
US6593322B1 (en) | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
YU26700A (sh) * | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
WO2001001969A2 (en) * | 1999-07-06 | 2001-01-11 | Endorecherche, Inc. | Methods of treating and/or suppressing weight gain |
EP1086692A3 (en) * | 1999-07-28 | 2003-07-09 | Pfizer Products Inc. | Estrogen agonists and antagonists for multiple indications |
US7790678B1 (en) | 1999-08-17 | 2010-09-07 | Immunopath Profile, Inc. | Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use |
US20070037777A1 (en) * | 2005-08-12 | 2007-02-15 | Immunopath Profile, Inc. | Lipid-containing compositions and methods of using them |
US6436977B1 (en) * | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
US6566081B1 (en) | 1999-10-06 | 2003-05-20 | The Brigham And Women's Hospital, Inc. | Methods of identifying a compound which modulates the non-transcriptional non-map-kinase induced effects of steroid hormones |
EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
CO5271709A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
CO5271696A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
CO5251465A1 (es) * | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
CZ20023223A3 (cs) * | 2000-04-07 | 2003-12-17 | Pfizer Products Inc. | Metabolity s agonisty/antagonisty estrogenu |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
ATE346159T1 (de) * | 2000-05-08 | 2006-12-15 | Pfizer Prod Inc | Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors |
HUP0202592A3 (en) * | 2000-06-01 | 2003-07-28 | Watson Pharmaceuticals Inc Cor | Transdermal delivery of lasofoxifene |
AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
JP2002117407A (ja) * | 2000-10-10 | 2002-04-19 | Satake Corp | 動画像検索方法及びその装置 |
IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
TWI303990B (en) | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
DE60108710T2 (de) * | 2000-11-30 | 2006-05-04 | Pfizer Products Inc., Groton | Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel |
JP2004515494A (ja) * | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | 治療剤 |
AU2002235348A1 (en) * | 2001-01-17 | 2002-07-30 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
US6599921B2 (en) | 2001-02-22 | 2003-07-29 | Nanodesign, Inc. | Non-steroidal estrogen receptor ligands |
AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
US20020182646A1 (en) * | 2001-04-30 | 2002-12-05 | Ke Huazhu | Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders |
PL366453A1 (en) * | 2001-05-01 | 2005-02-07 | Pfizer Products Inc. | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency |
US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
DK1397130T3 (da) | 2001-06-20 | 2007-11-12 | Wyeth Corp | Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1) |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
EP1312363A1 (en) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
WO2003055856A2 (en) | 2001-10-17 | 2003-07-10 | Bristol-Myers Squibb Company | BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) |
UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US7524866B2 (en) * | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040096510A1 (en) * | 2001-11-29 | 2004-05-20 | Steiner Mitchell S. | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20040213841A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S | Methods for treating hot flashes and gynecomastia |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US7342884B2 (en) * | 2002-03-13 | 2008-03-11 | Harmonic, Inc. | Method and apparatus for one directional communications in bidirectional communications channel |
RU2278861C2 (ru) * | 2002-03-28 | 2006-06-27 | Пфайзер Продактс Инк. | Очищенный лазофоксифен и способ очистки рацемического лазофоксифена рекристаллизацией |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US6608212B1 (en) * | 2002-06-04 | 2003-08-19 | Pfizer, Inc. | Process for preparing vinylaromatic compounds |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
JP4656939B2 (ja) | 2002-07-22 | 2011-03-23 | イーライ リリー アンド カンパニー | フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター |
US9315539B2 (en) * | 2002-10-01 | 2016-04-19 | Yale University | 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer |
UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
ES2325071T3 (es) | 2002-12-10 | 2009-08-25 | Wyeth | Derivados del acido indol-oxo-acetilaminoacetico sustituido como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1). |
DE60324183D1 (en) | 2002-12-10 | 2008-11-27 | Wyeth Corp | Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) |
MXPA05006282A (es) | 2002-12-10 | 2005-08-19 | Wyeth Corp | Derivados del acido 1h-indol-1-il acetico de 3-alquilo y 3-arilalquilo sustituido como inhibidores del inhibidor-1 de activador de plasminogeno (pai-1). |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
WO2004052855A2 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
WO2004058682A1 (ja) | 2002-12-26 | 2004-07-15 | Eisai Co., Ltd. | 選択的エストロゲン受容体モジュレーター |
US7332525B2 (en) | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
BRPI0406596A (pt) * | 2003-01-22 | 2005-12-20 | Pfizer Prod Inc | Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio |
JP2006525306A (ja) * | 2003-04-30 | 2006-11-09 | デビオファーム ソシエテ アノニム | ゴナドトロピン・ホルモン放出ホルモンを使用する方法及び組成物 |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
MXPA06003122A (es) * | 2003-09-19 | 2006-05-31 | Pfizer Prod Inc | Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos. |
US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
EP1696893A1 (en) * | 2003-12-17 | 2006-09-06 | Pfizer Products Incorporated | Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass. |
WO2005073205A1 (en) * | 2004-01-22 | 2005-08-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
WO2005073190A1 (en) * | 2004-01-29 | 2005-08-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
US20050203086A1 (en) * | 2004-03-04 | 2005-09-15 | Pfizer Inc. | Methods of treatment using an EP2 selective receptor agonist |
KR20060134146A (ko) | 2004-04-08 | 2006-12-27 | 와이어쓰 | 선택적 에스트로겐 수용체 모듈레이터로서의 바제독시펜아스코르베이트 |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
US7444197B2 (en) | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
BRPI0512342A (pt) * | 2004-06-21 | 2008-03-04 | Pharmacia & Upjohn Co Llc | métodos para aumento ósseo |
CN101039925A (zh) * | 2004-08-17 | 2007-09-19 | 詹森药业有限公司 | 作为选择性雌激素受体调节剂的苯并氧氮杂䓬衍生物 |
CN101044136A (zh) | 2004-08-23 | 2007-09-26 | 惠氏公司 | 作为pai-1抑制剂的吡咯基-萘基酸 |
BRPI0514572A (pt) | 2004-08-23 | 2008-06-17 | Wyeth Corp | ácidos de tiazolo-naftila |
US7754747B2 (en) | 2004-08-23 | 2010-07-13 | Wyeth Llc | Oxazolo-naphthyl acids |
AU2005308575A1 (en) * | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia |
BRPI0606871A2 (pt) | 2005-01-27 | 2009-07-21 | Wyeth Corp | "processos e compostos para a preparação de derivados de naftilindol substituìdos |
WO2006114702A2 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
ES2350853T3 (es) * | 2005-06-22 | 2011-01-27 | Pfizer Products Inc. | Procedimiento de hidrogenación estereoselectiva para preparar cis-6-fenil-5-[4-(2-pirrolidin-1-il-etoxi)-fenil]2-metoxi-5,6,7,8-tetrahidronaftaleno clorhidrato. |
ES2646326T3 (es) | 2005-08-03 | 2017-12-13 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina en el tratamiento de la obesidad |
JP2009504762A (ja) | 2005-08-17 | 2009-02-05 | ワイス | 置換インドール類およびそれらの使用方法 |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7923449B2 (en) | 2005-10-29 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
JP5212931B2 (ja) | 2006-01-26 | 2013-06-19 | 学校法人東京理科大学 | ラソフォキシフェン及びその類縁体の製造方法 |
CA2649938A1 (en) * | 2006-05-09 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
EP2037927B1 (en) * | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
CA2657043A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
MX2009001551A (es) | 2006-08-14 | 2009-02-20 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas. |
MX2009002031A (es) * | 2006-08-25 | 2009-03-06 | Boehringer Ingelheim Int | Sistema de liberacion controlada y metodo para fabricarlo. |
EP2094643B1 (en) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
WO2008090742A1 (ja) * | 2007-01-23 | 2008-07-31 | National University Corporation Hokkaido University | 眼疾患モデル用非ヒト動物 |
CZ2007373A3 (cs) * | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
US20090062374A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched lasofoxifene |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
CA2866905C (en) | 2007-10-16 | 2016-04-19 | Repros Therapeutics, Inc. | Selected estrogen receptor modulator (serm) for type 2 diabetes |
US8003689B2 (en) * | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
WO2010125578A2 (en) * | 2009-04-29 | 2010-11-04 | Glenmark Generics Limited | A process for the preparation of lasofoxifene tartrate |
WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
CN102311406A (zh) * | 2010-06-29 | 2012-01-11 | 武汉启瑞药业有限公司 | 拉索昔芬中间体的制备方法 |
CN102464629A (zh) * | 2010-11-12 | 2012-05-23 | 上海医药工业研究院 | 1-{2-[4-(6-甲氧基-2-苯基-3,4-二氢萘-1-基)苯氧基]乙基}吡咯烷的制备方法 |
EP2524908A1 (en) | 2011-05-20 | 2012-11-21 | LEK Pharmaceuticals d.d. | Process for the preparation of alfa-substituted ketones and their application in synthesis of pharmaceutically active compounds |
DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
CN102643178A (zh) * | 2012-02-08 | 2012-08-22 | 浙江华海药业股份有限公司 | 一种酒石酸拉索昔芬及其中间体的制备方法 |
US20150031656A1 (en) | 2012-02-29 | 2015-01-29 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
CN103113323B (zh) * | 2013-02-05 | 2015-11-11 | 南京华威医药科技开发有限公司 | 酒石酸拉索昔芬中间体的制备方法 |
WO2015092634A1 (en) * | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
EP4035664A3 (en) | 2014-03-28 | 2022-11-30 | Duke University | Treating cancer using selective estrogen receptor modulators |
DK3302471T3 (da) | 2015-05-29 | 2021-11-15 | Eisai R&D Man Co Ltd | Tetrasubstituerede alkenforbindelser og deres anvendelse |
WO2017080966A1 (en) * | 2015-11-09 | 2017-05-18 | F. Hoffmann-La Roche Ag | Tetrahydronaphthalene estrogen receptor modulators and uses thereof |
CN108348605B (zh) | 2015-11-10 | 2023-06-09 | 帕拉卡林治疗公司 | 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌 |
US9969732B2 (en) | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
NZ752443A (en) | 2016-10-11 | 2022-11-25 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
RU2747399C2 (ru) | 2016-11-28 | 2021-05-04 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соли производного индазола и их кристаллы |
CN111801098A (zh) | 2018-02-21 | 2020-10-20 | 人工智能治疗公司 | 使用阿匹莫德和谷氨酸能剂的组合疗法 |
US11497730B2 (en) | 2018-04-10 | 2022-11-15 | Duke University | Lasofoxifene treatment of breast cancer |
CN109317203B (zh) * | 2018-12-03 | 2019-09-03 | 毕云丽 | 一种治疗绝经后妇女骨质疏松症用药物中间体的制备方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3396169A (en) * | 1966-10-26 | 1968-08-06 | Upjohn Co | Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes |
US3274213A (en) * | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
US3234090A (en) * | 1962-09-10 | 1966-02-08 | Ciba Geigy Corp | Pharmaceutical compositions comprising saturated basic ethers |
US3227730A (en) * | 1963-05-01 | 1966-01-04 | Union Carbide Corp | Stabilization of lactones |
US3862232A (en) * | 1963-07-03 | 1975-01-21 | Upjohn Co | 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof |
US3293263A (en) * | 1963-12-09 | 1966-12-20 | Upjohn Co | Diphenylbenzocycloalkenes |
US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US3320271A (en) * | 1964-06-01 | 1967-05-16 | Upjohn Co | 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes |
US3483293A (en) * | 1967-12-15 | 1969-12-09 | Upjohn Co | Method for controlling birds and rodents |
US3567737A (en) * | 1968-01-02 | 1971-03-02 | Upjohn Co | Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes |
US3875242A (en) | 1968-01-02 | 1975-04-01 | Upjohn Co | Compounds and process for preparing the same |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4358593A (en) * | 1981-04-03 | 1982-11-09 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
DE4117512A1 (de) * | 1991-05-25 | 1992-11-26 | Schering Ag | 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5484798A (en) * | 1994-09-20 | 1996-01-16 | Eli Lilly And Company | Benzothiopene compounds, compositions, and method of inhibiting restenosis |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
US5532382A (en) * | 1995-03-13 | 1996-07-02 | Eli Lilly And Company | Benzothiophenes substituted at the 3-carbonyl |
US5567828A (en) * | 1995-06-07 | 1996-10-22 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
CA2448235A1 (en) * | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
DE102012218742A1 (de) | 2012-10-15 | 2014-04-17 | Deere & Company | Nachdrescheinrichtung für einen Mähdrescher |
-
1995
- 1995-01-09 US US08/369,954 patent/US5552412A/en not_active Ceased
- 1995-04-24 AT AT95914493T patent/ATE214382T1/de active
- 1995-04-24 CA CA002209925A patent/CA2209925C/en not_active Expired - Lifetime
- 1995-04-24 EP EP95914493A patent/EP0802910B1/en not_active Expired - Lifetime
- 1995-04-24 EP EP01120246A patent/EP1151998A1/en not_active Withdrawn
- 1995-04-24 PT PT95914493T patent/PT802910E/pt unknown
- 1995-04-24 US US08/849,726 patent/US6204286B1/en not_active Expired - Lifetime
- 1995-04-24 DK DK95914493T patent/DK0802910T3/da active
- 1995-04-24 JP JP8521528A patent/JP2972347B2/ja not_active Expired - Lifetime
- 1995-04-24 ES ES95914493T patent/ES2172579T3/es not_active Expired - Lifetime
- 1995-04-24 DE DE69525857T patent/DE69525857T2/de not_active Expired - Lifetime
- 1995-04-24 WO PCT/IB1995/000286 patent/WO1996021656A1/en active IP Right Grant
- 1995-04-24 EP EP20030026477 patent/EP1411049A1/en not_active Withdrawn
- 1995-04-24 DE DE122009000047C patent/DE122009000047I1/de active Pending
- 1995-12-14 AP APAP/P/1995/000774A patent/AP592A/en active
- 1995-12-22 CO CO95061202A patent/CO4600740A1/es unknown
- 1995-12-22 SK SK1648-95A patent/SK281992B6/sk not_active IP Right Cessation
- 1995-12-28 UA UA95125539A patent/UA46710C2/uk unknown
- 1995-12-30 TW TW084114170A patent/TW313567B/zh not_active IP Right Cessation
-
1996
- 1996-01-01 IL IL13076196A patent/IL130761A/xx not_active IP Right Cessation
- 1996-01-01 IL IL11664396A patent/IL116643A/xx not_active IP Right Cessation
- 1996-01-03 MA MA24123A patent/MA23768A1/fr unknown
- 1996-01-03 SG SG1996000020A patent/SG47377A1/en unknown
- 1996-01-03 MY MYPI96000009A patent/MY115784A/en unknown
- 1996-01-03 PE PE1996000003A patent/PE46597A1/es not_active Application Discontinuation
- 1996-01-04 AR ARP960100879A patent/AR003917A1/es unknown
- 1996-01-05 RU RU96100074A patent/RU2130454C1/ru active
- 1996-01-05 IS IS4316A patent/IS1916B/is unknown
- 1996-01-08 NO NO960081A patent/NO305435B1/no not_active IP Right Cessation
- 1996-01-08 CN CN96100634A patent/CN1059902C/zh not_active Expired - Lifetime
- 1996-01-08 ZA ZA9695A patent/ZA9695B/xx unknown
- 1996-01-08 KR KR1019960000199A patent/KR100190727B1/ko not_active IP Right Cessation
- 1996-01-08 RO RO96-00021A patent/RO116275B1/ro unknown
- 1996-01-08 RS YU596A patent/RS49531B/sr unknown
- 1996-01-08 LV LVP-96-04A patent/LV11460B/en unknown
- 1996-01-08 NZ NZ280792A patent/NZ280792A/en not_active IP Right Cessation
- 1996-01-08 CZ CZ9655A patent/CZ285085B6/cs not_active IP Right Cessation
- 1996-01-08 PL PL96312182A patent/PL183474B1/pl unknown
- 1996-01-09 OA OA60765A patent/OA10254A/en unknown
- 1996-01-09 HR HR960010A patent/HRP960010B1/xx not_active IP Right Cessation
- 1996-01-09 AU AU40916/96A patent/AU700982B2/en not_active Expired
- 1996-01-09 SI SI9600004A patent/SI9600004A/sl not_active IP Right Cessation
- 1996-01-09 TR TR96/00001A patent/TR199600001A2/xx unknown
- 1996-01-09 BG BG100278A patent/BG62256B1/bg unknown
- 1996-01-09 BR BR9600079A patent/BR9600079A/pt not_active IP Right Cessation
- 1996-01-09 EG EG1896A patent/EG23913A/xx active
- 1996-01-09 HU HU9600056A patent/HU224077B1/hu active Protection Beyond IP Right Term
- 1996-02-07 SA SA96160584A patent/SA96160584B1/ar unknown
-
1997
- 1997-07-08 FI FI972903A patent/FI116525B/fi not_active IP Right Cessation
-
1998
- 1998-08-28 US US09/141,613 patent/US6153622A/en not_active Expired - Lifetime
-
1999
- 1999-07-01 IL IL13076199A patent/IL130761A0/xx unknown
- 1999-12-17 US US09/466,034 patent/US6441193B1/en not_active Expired - Lifetime
-
2000
- 2000-10-24 IL IL13923500A patent/IL139235A0/xx unknown
-
2001
- 2001-03-28 US US09/820,158 patent/US20010025051A1/en not_active Abandoned
-
2002
- 2002-05-16 US US10/147,725 patent/US20020132816A1/en not_active Abandoned
-
2004
- 2004-12-23 US US11/022,427 patent/USRE39558E1/en not_active Expired - Lifetime
-
2009
- 2009-08-19 LU LU91599C patent/LU91599I2/fr unknown
- 2009-08-21 NO NO2009018C patent/NO2009018I2/no unknown
- 2009-08-24 NL NL300405C patent/NL300405I2/nl unknown
-
2010
- 2010-08-20 US US12/860,099 patent/US20100317712A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2009018I1 (no) | Lasofoksifen | |
BR9609171A (pt) | Fenilpiridazinonas | |
ATA135896A (de) | Skibob | |
BR9607795A (pt) | Fucopeptídeos | |
DE69633882D1 (de) | Spreizspektrumübertragungsgerät | |
FI953365A (fi) | Polkupy¦räteline | |
BR9603509A (pt) | Piperidinilmetiloxazolidinonas | |
ATE198470T1 (de) | Alkenyl-benzoylguanidine | |
BR9605050A (pt) | Filatório | |
ATE240972T1 (de) | Cyclopeptolide | |
ATA119896A (de) | Scheibenmähwerk | |
BR9503866A (pt) | Autolabor | |
BR9501643A (pt) | Helistato | |
FI2103U1 (fi) | Sanitetsystem | |
BR7501301U (pt) | Guarda-chuva-mochila | |
BR7500192U (pt) | Parasitofiltro | |
BR7500703U (pt) | Rodopratic | |
BR7501376U (pt) | Massarreal | |
BR7501399U (pt) | Ciclonavegador | |
BR7501426U (pt) | Búlica | |
FIU950059U0 (fi) | Kopplingsstycke foer en motorsaog | |
BR7501303U (pt) | Dupla-embalagem | |
BR7501299U (pt) | Geladeira-prática | |
BR7501298U (pt) | Torre-audio-visual | |
BR7501437U (pt) | Leiteira |